CN106822579A - Composition with treatment osteoporosis effect and its preparation method and application - Google Patents
Composition with treatment osteoporosis effect and its preparation method and application Download PDFInfo
- Publication number
- CN106822579A CN106822579A CN201611218454.1A CN201611218454A CN106822579A CN 106822579 A CN106822579 A CN 106822579A CN 201611218454 A CN201611218454 A CN 201611218454A CN 106822579 A CN106822579 A CN 106822579A
- Authority
- CN
- China
- Prior art keywords
- calcium
- composition
- extract
- fruit
- barrenwort
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 54
- 208000001132 Osteoporosis Diseases 0.000 title claims abstract description 49
- 230000000694 effects Effects 0.000 title claims abstract description 38
- 238000002360 preparation method Methods 0.000 title claims description 18
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims abstract description 63
- 239000011575 calcium Substances 0.000 claims abstract description 61
- 229910052791 calcium Inorganic materials 0.000 claims abstract description 55
- 239000000284 extract Substances 0.000 claims abstract description 55
- 239000003814 drug Substances 0.000 claims abstract description 45
- 244000241872 Lycium chinense Species 0.000 claims abstract description 38
- 235000015468 Lycium chinense Nutrition 0.000 claims abstract description 38
- 235000013399 edible fruits Nutrition 0.000 claims abstract description 38
- 235000018905 epimedium Nutrition 0.000 claims abstract description 37
- 241001016310 Epimedium grandiflorum Species 0.000 claims abstract description 35
- 108700016171 Aspartate ammonia-lyases Proteins 0.000 claims abstract description 34
- 239000002994 raw material Substances 0.000 claims abstract description 14
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 49
- 239000000843 powder Substances 0.000 claims description 19
- 150000001669 calcium Chemical class 0.000 claims description 13
- 238000000034 method Methods 0.000 claims description 12
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims description 11
- 238000001914 filtration Methods 0.000 claims description 10
- 241000514719 Mactra quadrangularis Species 0.000 claims description 9
- 239000012141 concentrate Substances 0.000 claims description 9
- 238000001816 cooling Methods 0.000 claims description 9
- 239000008188 pellet Substances 0.000 claims description 9
- 239000006228 supernatant Substances 0.000 claims description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 9
- 239000006286 aqueous extract Substances 0.000 claims description 8
- 239000002775 capsule Substances 0.000 claims description 8
- 239000008187 granular material Substances 0.000 claims description 8
- 239000003795 chemical substances by application Substances 0.000 claims description 7
- 239000000706 filtrate Substances 0.000 claims description 7
- 238000005119 centrifugation Methods 0.000 claims description 6
- 239000006187 pill Substances 0.000 claims description 6
- 238000001556 precipitation Methods 0.000 claims description 6
- 239000003937 drug carrier Substances 0.000 claims description 5
- 239000012669 liquid formulation Substances 0.000 claims description 5
- 238000000605 extraction Methods 0.000 claims description 3
- 239000000463 material Substances 0.000 claims description 3
- 239000002244 precipitate Substances 0.000 claims description 3
- 241000424773 Epimedium alpinum Species 0.000 claims description 2
- 238000005325 percolation Methods 0.000 claims description 2
- 238000010992 reflux Methods 0.000 claims description 2
- 241000040710 Chela Species 0.000 claims 1
- -1 Granula Substances 0.000 claims 1
- 210000000988 bone and bone Anatomy 0.000 abstract description 23
- 150000001413 amino acids Chemical class 0.000 abstract description 7
- 238000012360 testing method Methods 0.000 abstract description 6
- 238000002474 experimental method Methods 0.000 abstract description 4
- 238000005728 strengthening Methods 0.000 abstract description 2
- 230000003185 calcium uptake Effects 0.000 abstract 1
- 239000000470 constituent Substances 0.000 abstract 1
- 238000012423 maintenance Methods 0.000 abstract 1
- 230000002503 metabolic effect Effects 0.000 abstract 1
- 229960005069 calcium Drugs 0.000 description 44
- 229940079593 drug Drugs 0.000 description 15
- 241000700159 Rattus Species 0.000 description 10
- 210000002966 serum Anatomy 0.000 description 9
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 8
- 210000003734 kidney Anatomy 0.000 description 8
- 239000008101 lactose Substances 0.000 description 8
- 235000020985 whole grains Nutrition 0.000 description 8
- 229920002261 Corn starch Polymers 0.000 description 6
- 235000001014 amino acid Nutrition 0.000 description 6
- 229940024606 amino acid Drugs 0.000 description 6
- 235000008504 concentrate Nutrition 0.000 description 6
- 239000008120 corn starch Substances 0.000 description 6
- 229940099112 cornstarch Drugs 0.000 description 6
- 201000010099 disease Diseases 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 239000007788 liquid Substances 0.000 description 5
- 210000001672 ovary Anatomy 0.000 description 5
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 4
- 230000037182 bone density Effects 0.000 description 4
- 229910052500 inorganic mineral Inorganic materials 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 239000011707 mineral Substances 0.000 description 4
- 235000010755 mineral Nutrition 0.000 description 4
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 3
- 208000035896 Twin-reversed arterial perfusion sequence Diseases 0.000 description 3
- 208000027418 Wounds and injury Diseases 0.000 description 3
- 159000000007 calcium salts Chemical class 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- 230000007774 longterm Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 239000011574 phosphorus Substances 0.000 description 3
- 229910052698 phosphorus Inorganic materials 0.000 description 3
- DWNBOPVKNPVNQG-LURJTMIESA-N (2s)-4-hydroxy-2-(propylamino)butanoic acid Chemical compound CCCN[C@H](C(O)=O)CCO DWNBOPVKNPVNQG-LURJTMIESA-N 0.000 description 2
- 206010002091 Anaesthesia Diseases 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 206010012335 Dependence Diseases 0.000 description 2
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 2
- 210000000577 adipose tissue Anatomy 0.000 description 2
- 230000032683 aging Effects 0.000 description 2
- 230000037005 anaesthesia Effects 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 238000004140 cleaning Methods 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000019634 flavors Nutrition 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 230000036407 pain Effects 0.000 description 2
- 230000008506 pathogenesis Effects 0.000 description 2
- 108010048734 sclerotin Proteins 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 230000001502 supplementing effect Effects 0.000 description 2
- 210000002435 tendon Anatomy 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 238000003809 water extraction Methods 0.000 description 2
- 210000002417 xiphoid bone Anatomy 0.000 description 2
- 206010067484 Adverse reaction Diseases 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- 244000003416 Asparagus officinalis Species 0.000 description 1
- 235000005340 Asparagus officinalis Nutrition 0.000 description 1
- 208000010392 Bone Fractures Diseases 0.000 description 1
- RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 208000036119 Frailty Diseases 0.000 description 1
- RGHNJXZEOKUKBD-SQOUGZDYSA-N Gluconic acid Natural products OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 1
- 208000000913 Kidney Calculi Diseases 0.000 description 1
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
- 244000241838 Lycium barbarum Species 0.000 description 1
- 235000015459 Lycium barbarum Nutrition 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 206010029148 Nephrolithiasis Diseases 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 210000003489 abdominal muscle Anatomy 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000002180 anti-stress Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 206010003549 asthenia Diseases 0.000 description 1
- FCPVYOBCFFNJFS-LQDWTQKMSA-M benzylpenicillin sodium Chemical compound [Na+].N([C@H]1[C@H]2SC([C@@H](N2C1=O)C([O-])=O)(C)C)C(=O)CC1=CC=CC=C1 FCPVYOBCFFNJFS-LQDWTQKMSA-M 0.000 description 1
- 230000002146 bilateral effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 230000037118 bone strength Effects 0.000 description 1
- VSGNNIFQASZAOI-UHFFFAOYSA-L calcium acetate Chemical compound [Ca+2].CC([O-])=O.CC([O-])=O VSGNNIFQASZAOI-UHFFFAOYSA-L 0.000 description 1
- 235000011092 calcium acetate Nutrition 0.000 description 1
- 239000001639 calcium acetate Substances 0.000 description 1
- 229960005147 calcium acetate Drugs 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- MKJXYGKVIBWPFZ-UHFFFAOYSA-L calcium lactate Chemical compound [Ca+2].CC(O)C([O-])=O.CC(O)C([O-])=O MKJXYGKVIBWPFZ-UHFFFAOYSA-L 0.000 description 1
- 239000001527 calcium lactate Substances 0.000 description 1
- 229960002401 calcium lactate Drugs 0.000 description 1
- 235000011086 calcium lactate Nutrition 0.000 description 1
- 239000002729 catgut Substances 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 229960003276 erythromycin Drugs 0.000 description 1
- 230000035611 feeding Effects 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- 239000000174 gluconic acid Substances 0.000 description 1
- 235000012208 gluconic acid Nutrition 0.000 description 1
- 230000023597 hemostasis Effects 0.000 description 1
- 201000001881 impotence Diseases 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 239000010977 jade Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 235000019629 palatability Nutrition 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 229940100486 rice starch Drugs 0.000 description 1
- 239000013049 sediment Substances 0.000 description 1
- QGMRQYFBGABWDR-UHFFFAOYSA-N sodium;5-ethyl-5-pentan-2-yl-1,3-diazinane-2,4,6-trione Chemical compound [Na+].CCCC(C)C1(CC)C(=O)NC(=O)NC1=O QGMRQYFBGABWDR-UHFFFAOYSA-N 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000010025 steaming Methods 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 238000009810 tubal ligation Methods 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/29—Berberidaceae (Barberry family), e.g. barberry, cohosh or mayapple
- A61K36/296—Epimedium
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/81—Solanaceae (Potato family), e.g. tobacco, nightshade, tomato, belladonna, capsicum or jimsonweed
- A61K36/815—Lycium (desert-thorn)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
- A61K36/8969—Polygonatum (Solomon's seal)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation or decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Alternative & Traditional Medicine (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Engineering & Computer Science (AREA)
- Inorganic Chemistry (AREA)
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention discloses a kind of composition with treatment osteoporosis effect, it is made up of the raw material of following parts by weight：1 to 10 part of aspartase calcium, 1 to 10 part of the extract of barrenwort, the fruit of Chinese wolfberry and sealwort.The present invention screens the composition for obtaining by many experiments, calcium constituent replenishers and the use Chinese medicine composition compatibility amino acid organic calcium under guidance of traditional Chinese medicine theory, proportioning science is novel, test result indicate that, the composition that the present invention is provided can effectively treat osteoporosis, nourishing disney and strengthening bone, slow down the loss of bone, the effects such as improving bone mineralising, promote calcium uptake, maintenance calcium metabolic balance, safely and effectively, can be developed into the medicine for preventing and treating osteoporosis.
Description
Technical field
The present invention relates to a kind of composition, and in particular to a kind of composition and its preparation with treatment osteoporosis effect
Method and its application.
Background technology
According to statistics, global patients with osteoporosis has ranked the 7th more than 200,000,000 in the incidence of disease seniority among brothers and sisters of world's common disease
Name.China is the most country of patients with osteoporosis in the world, and current patient numbers are up to 90,000,000.Wherein more than 60 years old female
Property developing osteoporosis rate is up to 70%.With the increasingly aging of population, the incidence of disease of osteoporosis is also in synchronization
Growth trend.To be increased sharply to more than 200,000,000 to the year two thousand fifty China's patients with osteoporosis according to estimates, account for the 13.2% of population.With people
Class life-time dilatation and the arriving of aging society, the generation of osteoporosis are more and more, in the urgent need to research and development more
Safely and effectively to prevent and treat the medicine of osteoporosis.
Calcium-supplementing preparation is various both at home and abroad at present, but inorganic calcium salt occupies an leading position, and inorganic calcium salt is cheap but absorptivity
It is low easily to be stopped in kidney, cause the diseases such as kidney stone, such as calcium carbonate long-term taking there may be being hard and dry, lose the appetite, stomach
The side effects such as pain.Organic calcium salt there is also different toxic and side effects, and such as calcium lactate long-term taking easily produces fatigue；Gluconic acid
Calcium can cause blood sugar in diabetic patients to raise；Calcium acetate can cause diarrhoea etc..Amino acid chelated calcium is used as third generation calcium supplementing product
With good stability, absorptivity is high, and biological value is high, with disease-resistant anti-stress effect and small toxicity good palatability, using less, subtract
The features such as of low pollution is beneficial to environmental protection.The present invention using waste shell and pure amino acid as calcium source and origin of amino acid, by right
The screening of chelating condition and optimization, prepare amino acid chelated calcium, and with Herba Epimedii, the fruit of Chinese wolfberry and sealwort compatibility, with very
The good effect for preventing and treating osteoporosis.
Theory of traditional Chinese medical science thinks：Kidney storing essence, main bone, raw marrow, marrow are hidden in bone cavity, nourish bone, the dependence of growing of bone
The nourishing of kidney vital essence with promote, bone it is powerful with it is fragile be essence in kidney prosperity and decline important symbol.The full then bone of essence in kidney
Marrow biochemistry is active, and bone can just obtain the nourishing of marrow, and bone mineral content is normal and bone strong.Then kidney qi declines human senility, kidney
Smart empty few, medullization source is not enough, it is impossible to nutrition bone and the marrow that arrives is hollow, bone mineral content declines, thus osteoporosis occurs.
《Plain Questions impotence is discussed》Say：" bone is withered and marrow subtracts, and it is the atrophic debility of bones to send out for the kidney being in charge of bone and marrow ... heat in renal meridian, then failure of the spinal column to keep in upright position.”《Element
Ask that lunge section is discussed》Middle theory：" disease in bone, unable to raise the limbs due to heaviness of the bones, aching pain in the bone marrow, extremely, name says heumatism to cold air.”《Synopsis Golden Chamber》Retouching
Pointed out " addiction for sour flavor harming tendons, the injury of tendon and muscle ... ... addiction for salty flavor damaging bone, bone fracture is then withered, and name is said withered " when stating the pathogenesis that bone withers.
Currently for osteoporosis Western medicine and Chinese medicine in terms of osteoporosis is treated effect it is not notable, and Western medicine is at some
The infringement to body can be also caused in degree, cmm of simple prescription, proved recipe foundation are had nothing in common with each other, rules for the treatment of disunity.Therefore.According to sclerotin
The pharmaceutical preparation that this sick high effect nontoxic is treated in loose pathogenesis, positive searching and effort search has great importance.
The content of the invention
Goal of the invention：Present invention aim to address the deficiencies in the prior art, there is provided one kind proportioning is scientific and reasonable, and curative effect is true
Cut, Clinical practice safety, the composition of the low treatment osteoporosis of adverse reaction, it is a further object to provide the group
The preparation method of compound and its application in treatment medicine for treating osteoporosis is prepared.
Technical scheme：In order to realize the above object the technical scheme that the present invention takes is：
A kind of composition with treatment osteoporosis effect, it is made up of the raw material of following parts by weight：
1 to 10 part of aspartase calcium, 1 to 10 part of the extract of barrenwort, the fruit of Chinese wolfberry and sealwort.
Preferably, the above-described composition with treatment osteoporosis effect, it is by following parts by weight
Raw material be made：1 to 6 part of aspartase calcium, 1 to 6 part of the extract of barrenwort, the fruit of Chinese wolfberry and sealwort.
Preferably, the above-described composition with treatment osteoporosis effect, it is by following parts by weight
Raw material be made：1 part of aspartase calcium, 1 part of the extract of barrenwort, the fruit of Chinese wolfberry and sealwort.
Preferably, the above-described composition with treatment osteoporosis effect, described asparatate
Chelating calcium is prepared by the following method and obtains：Mactra veneriformis shell is taken, clean dry calcines 1- in 600-1000 DEG C of Muffle furnace
4h, pulverizes and sieves to obtain activated calcium powder CaO after cooling；
By Ca in asparatate and activated calcium powder CaO2+Mol ratio is 1~3:1~3, it is 4~6 in pH value, temperature is 60
After reacting 1~3h at~70 DEG C, centrifugation obtains supernatant, concentrates, and concentrate adds the ethanol to make ethanol final concentration of 65%~85%,
Precipitation, filtration, obtains ethanol pellet, dries, and obtains aspartase calcium.
Preferably, the above-described composition with treatment osteoporosis effect, described barrenwort, matrimony vine
The extract of son and sealwort is to be prepared by the following method to obtain：By 1~20：1~20：1~20 ratio takes barrenwort, the fruit of Chinese wolfberry
And sealwort, 5~10 times of water of volume of medicinal material are added, extract 1~3 time, 1~5 hour every time, merging filtrate, concentration obtained water extraction
Liquid is taken, be concentrated under reduced pressure dry barrenwort, the fruit of Chinese wolfberry and Rhizoma Polygonati extract.
Composition with treatment osteoporosis effect of the present invention, by each raw extract and pharmaceutically acceptable
Carrier prepare piece agent, granule, capsule, pill, the medicine of oral liquid formulation.
The composition with treatment osteoporosis effect that the present invention is provided, can be by the extract of each bulk drug and pharmacy
Upper acceptable carrier prepares piece agent, granule, capsule, pill, the medicine of oral liquid formulation.
The extract and carrier lactose or jade of each raw material when the extract of the composition that the present invention is provided is made capsule
Rice starch is well mixed, and whole grain is then encapsulated to be made capsule.
When the extract of each raw material of the composition that the present invention is provided is made oral liquid, the extract of each raw material is added into steaming
Distilled water dissolves, filtering, adds syrup, adjusts pH value, is made oral liquid.
When the extract of each raw material of the composition that the present invention is provided is made tablet, each raw material and lactose or corn are formed sediment
Powder, it is necessary to when add magnesium stearate lubricant, be well mixed, whole grain, then compressing tablet be made tablet.
When the extract of each raw material of the composition that the present invention is provided is made granule, extract and dilution each raw material
Agent lactose or cornstarch are well mixed, and whole grain is dried, and is made granule.
The preparation method of the composition with treatment osteoporosis effect of the present invention, comprises the following steps：
(1) Mactra veneriformis shell is taken, clean dry is placed in 600~1000 DEG C of Muffle furnaces and calcines 1-4h, is crushed after cooling
Sieve to obtain activated calcium powder CaO；It is 1~3 by Ca2+ mol ratios in asparatate and activated calcium powder CaO:1~3, it is 4 in pH value
~6, after reacting 1~3h at 50~80 DEG C, centrifugation obtains supernatant, concentrates, then plus ethanol make ethanol final concentration of 65%~
85%, precipitation, filtration obtains ethanol pellet, dries, and obtains aspartase calcium, standby；
(2) by 1~20：1~20：1~20 takes barrenwort, the fruit of Chinese wolfberry and sealwort, plus 5~10 times of water extractions 1~3 measured
Secondary, 1~5 hour every time, merging filtrate, concentration obtained barrenwort, the fruit of Chinese wolfberry and sealwort aqueous extract, is concentrated under reduced pressure excessively dry
The sheep leaves of pulse plants, the fruit of Chinese wolfberry and Rhizoma Polygonati extract, it is standby；
(3) parts by weight as described in any one of claims 1 to 3, take the asparagine that step (1) is prepared respectively
Barrenwort, the fruit of Chinese wolfberry and the Rhizoma Polygonati extract and pharmaceutically acceptable carrier that acid chelating calcium and step (2) are obtained prepare in blocks
Agent, granule, capsule, pill, the medicine of oral liquid formulation.
The preparation method of the composition with treatment osteoporosis effect of the present invention, the extraction described in step (2)
Method is：Decocting method, reflux extraction or percolation.
Composition answering in preventing and treating medicine for treating osteoporosis is prepared with treatment osteoporosis effect of the present invention
With.
Beneficial effect：Compared to the prior art, the present invention has the following advantages：
The present invention carries out prescription screening, group according to traditional Chinese medical theory and present-day medical knowledge using the theory of diagnosis and treatment
Compound proportioning is scientific and reasonable, test result indicate that, the composition that the present invention is provided has the comprehensive function of too many levels, Mutiple Targets,
Calcium balance in adjustable human body, supplementing calcium element and amino acid, nourishing disney and strengthening bone increase bone density and maintain bone mineral content, prevent
Control osteoporosis.The extract of the composition that the present invention is provided can facilitate and pharmaceutical carriers are prepared into various formulations in addition, face
It is convenient to take on bed, and test result indicate that the composition of present invention offer, using safety, long-term taking has no toxic side effect.Together
When the present invention provide Chinese medicine preparation preparation method, technological design rationally, effective component extracting content it is high, it is workable,
It is adapted to industrialized production.
Specific embodiment
With reference to specific embodiment, the present invention is furture elucidated, it should be understood that these embodiments be merely to illustrate the present invention and
Limitation the scope of the present invention is not used in, after the present invention has been read, those skilled in the art are to various shapes of equal value of the invention
The modification of formula falls within the application appended claims limited range.
Embodiment 1
The preparation method of the composition with treatment osteoporosis effect, comprises the following steps：
(1) Mactra veneriformis shell is taken, clean dry is calcined 4h in 600 DEG C of Muffle furnaces, pulverizes and sieves active after cooling
Calcium powder CaO.By Ca in asparatate and activated calcium powder CaO2+Mol ratio is 1:3, pH=4, after reacting 3h at 50 DEG C, from
The heart, obtains supernatant, concentration, plus ethanol makes Yi Chun Final concentration be 65%%, and precipitation, filtration obtains ethanol pellet, dries, and obtains day
L-aminobutanedioic acid chelates calcium；
(2) by 1：1：1 takes barrenwort, the fruit of Chinese wolfberry and sealwort, plus 5 times of water of amount are extracted 3 times, 2 hours every time, merge filter
Liquid, concentration, obtains aqueous extract, dry Chinese medicine mixed extract；
(3) by aspartase calcium and barrenwort, the fruit of Chinese wolfberry and sealwort Chinese medical extract by weight 1:10 mix
Afterwards, and lactose, cornstarch is well mixed, and whole grain is then encapsulated to be made capsule.
Embodiment 2
The preparation method of the composition with treatment osteoporosis effect, comprises the following steps：
(1) Mactra veneriformis shell is taken, clean dry is calcined 1h in 1000 DEG C of Muffle furnaces, pulverizes and sieves living after cooling
Property calcium powder CaO.By Ca in asparatate and activated calcium powder CaO2+Mol ratio is 3:1, pH=6, after reacting 1h at 80 DEG C, from
The heart, obtains supernatant, concentration, plus ethanol makes Yi Chun Final concentration be 80%, and precipitation, filtration obtains ethanol pellet, dries, and obtains Tianmen
Winter propylhomoserin chelates calcium；
(2) by 10：10：10 take barrenwort, the fruit of Chinese wolfberry and sealwort, plus 10 times of water of amount are extracted 2 times, 1 hour every time, are merged
Filtrate, concentration, obtains aqueous extract, dry Chinese medicine mixed extract；
(3) by aspartase calcium and barrenwort, the fruit of Chinese wolfberry and Rhizoma Polygonati extract by weight 10:After 1 mixes, plus
Enter diluent lactose or cornstarch is well mixed, whole grain, dry, be made granule.
Embodiment 3
The preparation method of the composition with treatment osteoporosis effect, comprises the following steps：
(1) Mactra veneriformis shell is taken, clean dry calcines 3h in 750 DEG C of Muffle furnaces, pulverizes and sieves to obtain calcium activated after cooling
Powder CaO.By Ca in asparatate and activated calcium powder CaO2+Mol ratio is 1:1.5, pH=4.5, after reacting 1.5h at 70 DEG C,
Centrifugation, obtains supernatant, concentrates, plus ethanol makes ethanol final concentration of 75%, precipitates, and filtration obtains ethanol pellet, dries, and obtains day
L-aminobutanedioic acid chelates calcium；
(2) by 10：1：1 takes barrenwort, the fruit of Chinese wolfberry and sealwort, plus 6 times of water of amount are extracted 2 times, 2 hours every time, merge filter
Liquid, concentration, obtains aqueous extract, dry Chinese medical extract；
(3) by aspartase calcium and barrenwort, the fruit of Chinese wolfberry and sealwort Chinese medical extract by weight 1:6 mix
Afterwards, add diluent lactose or cornstarch well mixed, whole grain is dried, and is made pill.
Embodiment 4
The preparation method of the composition with treatment osteoporosis effect, comprises the following steps：
(1) Mactra veneriformis shell is taken, clean dry is calcined 1.5h, pulverizes and sieves active after cooling in 850 DEG C of Muffle furnaces
Calcium powder CaO.It is 1.5 by Ca2+ mol ratios in asparatate and activated calcium powder CaO:1, pH=7, react 1.5h at 65 DEG C
Afterwards, it is centrifuged, obtains supernatant, concentrates, plus ethanol makes Yi Chun Final concentration be 60%, precipitation, filtration obtains ethanol pellet, dries, and obtains
Aspartase calcium；
(2) by 10：20：20 take barrenwort, the fruit of Chinese wolfberry and sealwort, plus 8 times of water of amount are extracted 1 time, 3 hours every time, are merged
Filtrate, concentration, obtains aqueous extract, dry Chinese medical extract；
(3) by aspartase calcium and barrenwort, the fruit of Chinese wolfberry and Rhizoma Polygonati extract by weight 6:After 1 mixes, and
Lactose, cornstarch is well mixed, and adds magnesium stearate lubricant, is well mixed, whole grain, dries, and then compressing tablet is made tablet.
Embodiment 5
The preparation method of the composition with treatment osteoporosis effect, comprises the following steps：
(1) Mactra veneriformis shell is taken, clean dry is calcined 2.5h, pulverizes and sieves active after cooling in 950 DEG C of Muffle furnaces
Calcium powder CaO.It is 1 by Ca2+ mol ratios in asparatate and activated calcium powder CaO:2, pH=7, after reacting 1.5h at 80 DEG C,
Centrifugation, obtains supernatant, concentrates, plus ethanol makes ethanol final concentration of 60%, precipitates, and filtration obtains ethanol pellet, dries, and obtains day
L-aminobutanedioic acid chelates calcium；
(2) by 10：10：10 take barrenwort, the fruit of Chinese wolfberry and sealwort, plus 7 times of water of amount are extracted 3 times, 1 hour every time, are merged
Filtrate, concentration, obtains aqueous extract, dry Chinese medicine mixed extract；
(3) by aspartase calcium and barrenwort, the fruit of Chinese wolfberry and Rhizoma Polygonati extract, by weight 10:After 10 mix,
Add diluent lactose or cornstarch well mixed, whole grain is dried, and is made granule.
The pharmacological experiment study of embodiment 6
1. experimental animal
SD rats, cleaning grade, female, 200~230g is purchased from Nanjing Medical University's Experimental Animal Center, credit number：
SCXK(Beijing)2012-0001。
2. Experimental agents
2.1 positive drugs：Happy power calcium (1~2/d), mineral company of the U.S., lot number：X000CU2S95.
2.2 test medicines：
Chinese medical extract (the 10g of the barrenwort, the fruit of Chinese wolfberry and the sealwort that are prepared respectively by the method for the embodiment of the present invention 1
Crude drug/kg)；Aspartase calcium (10g crude drugs/kg)；
The aspartase calcium that the method for embodiment 1 is prepared and barrenwort, the fruit of Chinese wolfberry and Rhizoma Polygonati extract weight
Portion rate is 1:10, dosage is divided into low dose group：Aspartase calcium (0.5g crude drugs/kg), Chinese medicine mixing is extracted
Thing (5g crude drugs/kg) and high dose group：Aspartase calcium (1g crude drugs/kg) and Chinese medicine mixed extract (10g crude drugs/
Kg) composition；
The aspartase calcium that the method for embodiment 2 is prepared, with barrenwort, the fruit of Chinese wolfberry and Rhizoma Polygonati extract weight
Portion rate is 10:1, dosage is divided into low dose group：Aspartase calcium (5g crude drugs/kg), Chinese medicine mixed extract
(0.5g crude drugs/kg) and high dose group：Aspartase calcium (10g crude drugs/kg) and Chinese medicine mixed extract (1g crude drugs/
Kg) composition；
3. experimental technique
3.1 aspartase calcium compatibility barrenwort, the fruit of Chinese wolfberry and sealwort Chinese medicine mixed extract are to ovariectomized female rats
The influence of osteoporosis model
Female rats are raised two weeks, after being randomly divided into 8 groups, i.e. sham-operation group, model after body weight increase to 230-260g
Group, positive drug group, aspartase calcium group, the Chinese medical extract group of barrenwort, the fruit of Chinese wolfberry and sealwort, the embodiment of the present invention
1 and the composition low dose group for preparing of embodiment 2, composition high dose group.All animal feedings are consistent, freely take the photograph
Food and drinking-water, removal ovary operation is implemented to rat.3% Nembutal sodium solution (40mg/kg, i.e. 0.2ml/100g) intraperitoneal injection
Anesthesia, anesthesia postabdomen fixes rat upwards, and cropping scope 4cm*3cm carries out hair cleaning under xiphoid-process.Operative site is used
75% alcohol carries out disinfection, and spreads hole towel, at about 1.5cm under xiphoid-process, longitudinal cut is done along hunter's line, and otch is about 1.7cm,
Abdominal muscles and peritonaeum are separated, abdominal cavity is exposed.Carefully ovary is carefully found upwards along uterus inferior horn, then slowly carry ovary
Go out, with catgut tubal ligation and its peripheral adipose tissue and blood vessel.Model group, positive drug group, aspartase calcium
Group, barrenwort, the fruit of Chinese wolfberry and Rhizoma Polygonati extract group, the rat of composition high and low dose group completely extracts bilateral ovaries；Sham-operation
Group rat takes out equivalent adipose tissue around ovary.Carefully hemostasis, is layered suture operation otch.Outer wound coats erythromycin medicine
Cream, intramuscular injection Benzylpenicillin sodium salt, daily 200,000 unit, continuous 5d.
After each group wound is recovered, start gavage within the 7th day and treat 3 months.Gastric infusion, one time a day, according to body weight 1
Week adjustment single administration amount.Specific experiment the results are shown in Table 1.
The each group of table 1 is to ovariectomized female rats serum biochemistry measurement result (x ± SD)
Note：Compare with model group,*P<0.05,**P<0.01；Compare with aspartase calcium group,#P<0.05；##P<
0.01；Compare with Chinese medical extract group,△P<0.05,△△P<0.01
It can be seen from the experimental result of table 1, compared with sham-operation group, serum calcium, serum phosphorus levels substantially reduce (P to model group<
0.01), the serum BALP and significantly raised (P of TRAP contents<0.01) explanation modeling success.Happy power calcium group and embodiment 1 and implementation
The aspartase calcium and traditional Chinese medicine extract composition that example 2 is prepared compare with model control group, serum calcium, phosphorus content
Significantly raised (P<0.01 or 0.05), serum BALP and TRAP content substantially reduces (P<0.01 or 0.05).With single lucid asparagus
Propylhomoserin chelates calcium group and single Chinese medical extract group compares, and serum calcium, serum phosphorus levels conspicuousness raise (P<0.05), serum
The reduction of BALP and TRAP contents conspicuousness.Test result indicate that in aspartase calcium and barrenwort, the fruit of Chinese wolfberry and sealwort
There are good anti-ovariectomized female rats to cause the effect of osteoporosis after medicine mixed extract compatibility.
The Rat Skeletal index (n=12) of table 2
Note：Compare with model group,*P<0.05,**P<0.01；Compare with aspartase calcium group,#P<0.05；##P<
0.01；Compare with Chinese medical extract group,△P<0.05,△△P<0.01。
Understand that compared with sham-operation group, bone density is decreased obviously model group according to table 2, happy power calcium group and embodiment 1 and implement
The aspartase calcium and traditional Chinese medicine extract composition that example 2 is prepared compare with model control group, and bone density has significantly
Increase, meanwhile, embodiment 1 and embodiment 2 compare with single aspartase calcium group and single Chinese medical extract group, drug effect
It is more excellent, using Chinese medicine composition and amino acid organic calcium compatibility, achieve extraordinary synergistic effect.
The present invention carries out Chinese prescription sieve according to traditional Chinese medical theory and present-day medical knowledge using the theory of diagnosis and treatment
Choosing, composition proportioning it is scientific and reasonable, by more than test result indicate that, the present invention provide composition can effectively prevent and treat sclerotin
It is loose, with bone density is increased, bone strength effect is improved, it is expected to develop into the new medicine for preventing and treating osteoporosis.
The above is only the preferred embodiment of the present invention, it is noted that for the ordinary skill people of the art
For member, under the premise without departing from the principles of the invention, some improvements and modifications can also be made, these improvements and modifications also should
It is considered as protection scope of the present invention.
Claims (9)
1. it is a kind of with the composition for treating osteoporosis effect, it is characterised in that it is made up of the raw material of following parts by weight：
1 to 10 part of aspartase calcium, 1 to 10 part of the extract of barrenwort, the fruit of Chinese wolfberry and sealwort.
2. it is according to claim 1 with the composition for treating osteoporosis effect, it is characterised in that it is by following weight
The raw material of number is made：1 to 6 part of aspartase calcium, 1 to 6 part of the extract of barrenwort, the fruit of Chinese wolfberry and sealwort.
3. it is according to claim 1 with the composition for treating osteoporosis effect, it is characterised in that it is by following weight
The raw material of number is made：1 part of aspartase calcium, 1 part of the extract of barrenwort, the fruit of Chinese wolfberry and sealwort.
4. according to any one of claims 1 to 3 with treatment osteoporosis effect composition, it is characterised in that institute
The aspartase calcium stated is prepared by the following method and obtains：Take Mactra veneriformis shell, clean dry, 600-1000 DEG C of horse
1-4h is not calcined in stove, activated calcium powder CaO is pulverized and sieved to obtain after cooling；
By Ca in asparatate and activated calcium powder CaO2+Mol ratio is 1~3:1~3, it is 4~6 in pH value, temperature is 60~70
After reacting 1~3h at DEG C, centrifugation obtains supernatant, concentrates, and concentrate adds the ethanol to make ethanol final concentration of 65%~85%, precipitates,
Filtration, obtains ethanol pellet, dries, and obtains aspartase calcium.
5. according to any one of claims 1 to 3 with treatment osteoporosis effect composition, it is characterised in that institute
The extract of barrenwort, the fruit of Chinese wolfberry and the sealwort stated is to be prepared by the following method to obtain：By 1~20：1~20：1~20 ratio
Barrenwort, the fruit of Chinese wolfberry and sealwort are taken, 5~10 times of water of volume of medicinal material are added, extracted 1~3 time, 1~5 hour every time, merged
Filtrate, concentration, obtains aqueous extract, and be concentrated under reduced pressure dry barrenwort, the fruit of Chinese wolfberry and Rhizoma Polygonati extract.
6. described in any one of claims 1 to 3 with treatment osteoporosis effect composition, it is characterised in that Jiang Geyuan
Material extract and pharmaceutically acceptable carrier prepare piece agent, granule, capsule, pill, the medicine of oral liquid formulation.
7. the preparation method of the composition with treatment osteoporosis effect described in any one of claims 1 to 3, its feature exists
In comprising the following steps：
(1) Mactra veneriformis shell is taken, clean dry is placed in 600~1000 DEG C of Muffle furnaces and calcines 1-4h, pulverized and sieved after cooling
Obtain activated calcium powder CaO；By Ca in asparatate and activated calcium powder CaO2+Mol ratio is 1~3:1~3, it is 4~6 in pH value,
After reacting 1~3h at 50~80 DEG C, centrifugation obtains supernatant, concentrates, and then adds ethanol to make ethanol final concentration of 65%~85%,
Precipitation, filtration, obtains ethanol pellet, dries, and obtains aspartase calcium, standby；
(2) by 1~20：1~20：1~20 takes barrenwort, the fruit of Chinese wolfberry and sealwort, plus 5~10 times amount water extract 1~3 time, often
Secondary 1~5 hour, merging filtrate, concentration obtained barrenwort, the fruit of Chinese wolfberry and sealwort aqueous extract, dry the barrenwort that is concentrated under reduced pressure,
The fruit of Chinese wolfberry and Rhizoma Polygonati extract, it is standby；
(3) parts by weight as described in any one of claims 1 to 3, take the asparatate chela that step (1) is prepared respectively
Close barrenwort, the fruit of Chinese wolfberry and Rhizoma Polygonati extract that calcium and step (2) obtain and pharmaceutically acceptable carrier preparation piece agent,
Granula, capsule, pill, the medicine of oral liquid formulation.
8. according to claim 7 with the preparation method for treating the composition that osteoporosis is acted on, it is characterised in that：Step
Suddenly the extracting method described in (2) is：Decocting method, reflux extraction or percolation.
9. the composition with treatment osteoporosis effect described in any one of claims 1 to 3 prevents and treats osteoporosis in preparation
Application in medicine.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201611218454.1A CN106822579B (en) | 2016-12-26 | 2016-12-26 | Composition with osteoporosis treatment effect and preparation method and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201611218454.1A CN106822579B (en) | 2016-12-26 | 2016-12-26 | Composition with osteoporosis treatment effect and preparation method and application thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN106822579A true CN106822579A (en) | 2017-06-13 |
| CN106822579B CN106822579B (en) | 2020-09-01 |
Family
ID=59135782
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201611218454.1A Active CN106822579B (en) | 2016-12-26 | 2016-12-26 | Composition with osteoporosis treatment effect and preparation method and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN106822579B (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107296879A (en) * | 2017-06-23 | 2017-10-27 | 张岐山 | It is a kind of to increase the composition and preparation method of bone density preventing bone rarefaction |
| CN108114239A (en) * | 2018-01-22 | 2018-06-05 | 武汉维奥制药有限公司 | A kind of capsule for increasing bone density and preparation method thereof |
| CN111671821A (en) * | 2020-07-06 | 2020-09-18 | 无锡市第九人民医院 | Formula of health-care product for improving osteoporosis |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1488638A (en) * | 2002-10-10 | 2004-04-14 | 上海海天医药科技开发有限公司 | Barrenwort total falvone extracting method and product made from said extract |
-
2016
- 2016-12-26 CN CN201611218454.1A patent/CN106822579B/en active Active
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1488638A (en) * | 2002-10-10 | 2004-04-14 | 上海海天医药科技开发有限公司 | Barrenwort total falvone extracting method and product made from said extract |
Non-Patent Citations (2)
| Title |
|---|
| 蒋金来: ""以四角蛤蜊为原料制备复合氨基酸螯合钙的研究"", 《中国优秀硕士学位论文数据库 医药卫生科技辑》 * |
| 陈发胜等: ""固肾汤治疗绝经后骨质疏松症的临床观察"", 《河北中医》 * |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107296879A (en) * | 2017-06-23 | 2017-10-27 | 张岐山 | It is a kind of to increase the composition and preparation method of bone density preventing bone rarefaction |
| CN108114239A (en) * | 2018-01-22 | 2018-06-05 | 武汉维奥制药有限公司 | A kind of capsule for increasing bone density and preparation method thereof |
| CN111671821A (en) * | 2020-07-06 | 2020-09-18 | 无锡市第九人民医院 | Formula of health-care product for improving osteoporosis |
Also Published As
| Publication number | Publication date |
|---|---|
| CN106822579B (en) | 2020-09-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR20150105714A (en) | composition for health functional food improving joint health | |
| CN101297889B (en) | Chinese medicine preparation for treating foot-and-mouth disease and preparation method thereof | |
| CN102823857A (en) | Ginseng donkey-hide gelatin healthcare food | |
| CN105533574A (en) | Toxin removing and body slimming green plum fruit and production technology thereof | |
| CN106822579A (en) | Composition with treatment osteoporosis effect and its preparation method and application | |
| KR20130009901A (en) | Health food composition for improving blood circulation, strengthening energy and preventing osteoporosis | |
| CN103784754A (en) | Capsules with effects of tonifying kidney and strengthening yang and preparation method thereof | |
| RU2174003C1 (en) | Pharmaceutical curative composition, method of curative and curative- prophylactic use of thereof | |
| CN101698061A (en) | Chinese medicinal liquor for nourishing yin and strengthening yang | |
| CN103800635A (en) | Medicinal and edible two-purpose composition for preventing and treating coronary heart disease and preparation method thereof | |
| KR100795663B1 (en) | A sulfur | |
| CN107233491A (en) | It is a kind of to improve the antifatigue maca composition of energy | |
| CN106177634A (en) | A kind of weight-reducing compound preparation and preparation method thereof | |
| CN1270737C (en) | Drug for treating gout and method for preparing pill thereof | |
| CN102106999A (en) | Chinese medicinal compound preparation for treating dysphagia due to stroke and preparation method thereof | |
| CN104491338B (en) | A kind of medicine-food dual-purpose composition to relax bowel and preparation method thereof | |
| KR100736594B1 (en) | Composition of health food for curing constipation and improving belly fatness and method producing thereof | |
| CN104800487B (en) | It is a kind of to be used to treat traditional Chinese medicinal ointment of chronic constipation and preparation method thereof | |
| CN103689298B (en) | Feed being used for the treatment of cad pig and preparation method thereof | |
| CN103550333A (en) | Composition for appetizing and reducing blood pressure | |
| CN114949022B (en) | Traditional Chinese medicine composition for treating tumors | |
| CN107149050A (en) | Chinese herbal feed additive for laying hen health care and preparation method thereof | |
| CN107115424A (en) | Change acidic constitution and protect calcium and clearing heat and detoxicating Chinese medicine composition and preparation method | |
| CN106389647A (en) | Medicine for treating blood diseases | |
| CN106975023A (en) | A kind of ox ORS and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| TR01 | Transfer of patent right | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20210125 Address after: 202450 3rd floor, No.6 Yucai lane, Caiyuan Town, Shengsi County, Zhoushan City, Zhejiang Province Patentee after: ZHEJIANG HAIFU MARINE BIOTECHNOLOGY Co.,Ltd. Address before: No.138 Xianlin Avenue, Qixia District, Nanjing City, Jiangsu Province Patentee before: Nanjing University of Chinese Medicine |